Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

NCT02923986 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped No enrollment

Conditions

Chronic Myelogenous Leukemia, Ph1-Positive
Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: BP1001 (varying dose)
DRUG: BP1001 (fixed dose)
DRUG: Dasatinib

Sponsor

Bio-Path Holdings, Inc.